No Prescription |
 |
 | ||
|
Lovir Zovirax |
|
| ||
No Prescription » Prescription Drugs 10 » Lovir Zovirax LOVIR Dispersible tablets are indicated for:Treatment of Herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. Suppression (prevention of recurrences) of recurrent Herpes simplex infections in immune-competent patients. Prophylaxis of Herpes simplex infections in immune-compromised patients. Treatment of acute Herpes zoster (shingles) infections for the reduction of the duration and severity of acute symptoms and rash for the reduction of all zoster-associated pain and for the reduction of the incidence and duration of post-herpetic neuralgia. Management of patients with severe AIDS who have a CD4 count of less than 50/żL. Studies have shown that oral aciclovir given in conjunction with anti-retroviral therapy reduced mortality in patients with advanced HIV disease. Patients undergoing allogenic bone marrow transplantation who are at risk of developing CMV infection while immunosuppressed (preceded by one month's treatment with intravenous aciclovir). Studies have shown that oral aciclovir reduced mortality in allogenic bone marrow transplant recipients. In addition oral aciclovir provided effective prophylaxis for herpes virus disease. Dosage and AdministrationDosage for treatment of Herpes simplex in adults For treatment of Herpes simplex infections one 200 mg LOVIR tablet should be taken five times daily at approximately four-hourly intervals.Treatment should continue for 5 days but in severe initial infections may have to be extended.Dosing should begin as early as possible after the start of an infection. For recurrent episodes this should preferably be during the prodromal period or when lesions first appear.In severely immunocompromised patients (e.g. after bone marrow transplant) or in patients with impaired absorption from the gut the dose can be doubled to 400 mg or alternatively intravenous administration should be considered.Dosage for Suppression of Herpes simplex in AdultsFor suppression of Herpes simplex infections in immune-competent patients one 200 mg LOVIR tablet should be taken four times daily at approximately six-hourly intervals.Many patients may be conveniently managed on a regimen of one 400 mg LOVIR tablet taken twice daily at approximately twelve-hourly intervals.Dosage titration down to one 200 mg LOVIR tablet taken thrice daily at approximately eight-hourly intervals or even twice daily at approximately twelve-hourly intervals may prove effective. Some patients may experience breakthrough infections on total daily doses of 800 mg aciclovir.Therapy should be interrupted periodically at intervals of six to twelve months in order to observe possible changes in the natural history of the disease.Dosage for Prophylaxis of Herpes simplex in AdultsFor prophylaxis of Herpes simplex infections in immunocompromised patients 200 mg aciclovir should be taken four times daily at approximately six-hourly intervals.In severely immunocompromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut the dose can be doubled to 400 mg or alternatively intravenous dosing could be considered.The duration of prophylactic administration is determined by the duration of the period at risk.Dosage for Treatment of Herpes zoster in AdultsFor treatment of Herpes zoster infections 800 mg aciclovir should be taken five times daily at approximately four-hourly intervals. Treatment should continue for seven days.In severely immunocompromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut consideration should be given to intravenous dosing. Dosing should begin as early as possible after the start of an infection: Treatment yields better results if initiated as soon as possible after onset of the rash ideally within 48 hours but up to 72 hours being acceptable.Use in Children For treatment of Herpes simplex infections and for prophylaxis of Herpes simplex infections in the immunocompromised children over the age of 2 years should be given adult doses and children below the age of 2 years should be given half the adult dose. No specific data are available on the suppression of Herpes simplex infections or the treatment of Herpes zoster infections in immunocompetent children. Buy Lovir Zovirax and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About Lovir Zovirax: Product Type: Prescription Drugs 10 Lovir ( Zovirax Generic Aciclovir ) Lovir (Zovirax Generic Aciclovir) Zovirax Generic Aciclovir 200mg Zovirax Generic Aciclovir Lovir
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
